resection and consideration of adjuvant chemotherapy (AC) based on patient and tumor characteristics. The role of AC in colon cancer is supported by the results of NSABP C01, 1 a pooled analysis, 2 and the MOSAIC trial 3 showing improvement in disease
Search Results
Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama, and Manisha Palta
Daniel Morgensztern and Ramaswamy Govindan
GV Fossati R Torri V . Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer . J Natl Cancer Inst 2003 ; 95 : 1453 – 1461 . 9. Waller D Peake MD Stephens RJ . Chemotherapy for
Christopher M. Booth, Sulaiman Nanji, Xuejiao Wei, Yingwei Peng, James J. Biagi, Timothy P. Hanna, Monika K. Krzyzanowska, and William J. Mackillop
Background International treatment guidelines have recommended 5-fluorouracil (FU)–based adjuvant chemotherapy (ACT) for patients with stage III colon cancer since the 1990s. 1 This is based on a series of randomized controlled trials (RCTs
Li-Ting Liu, Qiu-Yan Chen, Lin-Quan Tang, Shan-Shan Guo, Ling Guo, Hao-Yuan Mo, Yang Li, Qing-Nan Tang, Xue-Song Sun, Yu-Jing Liang, Chong Zhao, Xiang Guo, Chao-Nan Qian, Mu-Sheng Zeng, Jin-Xin Bei, Ming-Huang Hong, Jian-Yong Shao, Ying Sun, Jun Ma, and Hai-Qiang Mai
improve these results, additional systemic therapy has been explored, such as adding neoadjuvant or adjuvant chemotherapy (NACT or ACT, respectively) to concurrent chemoradiotherapy (CCRT). 7 – 12 However, due to inconsistent results of several
Paul J. Speicher, Lin Gu, Xiaofei Wang, Matthew G. Hartwig, Thomas A. D'Amico, and Mark F. Berry
Background Adjuvant chemotherapy (AC) after resection of stages II through IIIA non–small cell lung cancer (NSCLC) has repeatedly been shown to improve survival. 1 – 6 NCCN and ASCO therefore both recommend AC for patients with completely
Data adapted from Bergstrom et al. 1 Data based on reporting from 750 community oncology practices in the United States to McKesson Specialty Care Solutions. Adjuvant chemotherapy for breast cancer has evolved over several decades
Nina N. Sanford, Todd A. Aguilera, Michael R. Folkert, Chul Ahn, Brandon A. Mahal, Herbert Zeh, Muhammad S. Beg, John Mansour, and David J. Sher
Background Multiple randomized trials have shown improved survival with the addition of adjuvant chemotherapy after surgical resection for patients with pancreatic adenocarcinoma. 1 – 5 In 2000, the NCCN Clinical Practice Guidelines in Oncology
Gayathri Nagaraj and Cynthia X. Ma
. Describe the ideal treatment with adjuvant chemotherapy for patients with estrogen receptor (ER)-positive HER2-negative lymph node-negative breast cancer. Case Report A 67-year-old otherwise healthy postmenopausal woman presented for adjuvant
Viola Walter, Daniel Boakye, Janick Weberpals, Lina Jansen, Walter E. Haefeli, Uwe M. Martens, Phillip Knebel, Jenny Chang-Claude, Michael Hoffmeister, and Hermann Brenner
primarily treated by surgery, followed by adjuvant chemotherapy under certain conditions. Adjuvant treatment of stage II colon cancer is controversial 3 and mostly restricted to high-risk patients. 4 – 7 However, adjuvant chemotherapy has been widely
Matthew D. Galsky, Harry W. Herr, and Dean F. Bajorin
Advanced Bladder Cancer Meta-analysis Collaboration . Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis . Lancet 2003 ; 361 : 1927 – 1934 . 21 Bono AV Benvenuti C Reali L . Adjuvant chemotherapy in
